Development↦Management↦Informed Consent Process↦Procedures
What is it? Why is it important?
The Informed Consent Process (ICP) describes procedures used to obtain participant:
- Consent for study participation
- Re-consent for study participation during study conduct (i.e. due to changes potentially affecting participant willingness to remain in the study)
The key steps in the ICP are to:
- Assess the participant’s eligibility (e.g. compliance with study inclusion & exclusion criteria)
- Hand out the Participant Information Sheet (PIS) and explain the study to the participant (e.g. study design, intervention, safety issues, time investment, further-use of study data and biological material)
- Answer questions the participant may have, and to provide the participant with ample time to decide on study participation
- Sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF), once the participant has agreed to participate in the study
- Provide the participant with a signed copy of the ICF
- Document study inclusion in the patient file and the study database
- File the ICF in the ISF
More
The implementation of an ICP can face increasing challenges due to:
- The target population of the study (e.g. healthy volunteers, pregnant women, children, adolescents, persons unable to give consent)
- The complexity of the study (e.g. placebo controlled studies, emergency situations, inclusion of legal representatives)
- Increased study risks (e.g. first in man, intervention with novel drugs lacking extensive safety profiles, vulnerable target population)
- The collection of biological material and health related persona data for further-use projects
In the event of a substantial amendment during study conduct, participants should:
- Be informed about the changes including potential consequences (e.g. additional safety concerns, sampling of biological material, visits, data collection, and time investments)
- Re-consent to amended study procedures by dating and signing an updated ICF, approved by the EC
What do I need to do?
As a SP-INV, describe:
- ICP procedures applicable to your study in an SOP or study protocol
- Means on how to inform and obtain consent (e.g. in writing and/or orally, exemption from the written form)
- How to document consent (e.g. in patient file, study database)
- The timing of consent (e.g. with study procedures planned the same day, or post-hoc, incomplete information, step-wise consent)
- How to document ICP deviations (e.g. note to file)
Additional aspects to include:
- The use of advertisement
- Participant remuneration procedures
- Handling of data and biological material from participants who withdrew from the study, or were lost to follow-up
To ensure that the ICP is correctly implemented during study conduct, ensure that:
- Study staff remains trained on the SOP and are informed about potential changes
- Study staff authorized to carry out the ICP are defined in a delegation log
- Only EC approved documents (ICF, PIS) are used (e.g. document management)
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissethics – see in particular:
- Checklist for the recruitment of study participants by means of advertising
- Specimen text for advertisement
- Guidelines on the retention period of biological material and personal data of further-use projects without consent
- Conception and application of an electronic informed consent
- Time for consideration
- Monetary contributions to patients participating in research projects
References
ICH GCP E6(R2) – see in particular guideline
- 4.8. Informed consent of trial subjects
Declaration of Helsinki – see in particular principles
- 25 – 32 Informed Consent
ISO 14155:2020 Medical devices (access liable to costs) - see in particular sections
- 5.8 Informed consent
Swiss Law
HRA – see in particular articles and chapters
- Art. 16 Informed consent
- Art. 17 Consent to further use for research
- Art. 18 Incomplete consent
- Chapter 3, section 1. Research involving children, adolescents, adults lacking capacity.
- Chapter 3, section 2. Research involving pregnant women, IFV embryos, foetuses
- Chapter 3, section 3. Research involving prisoners
- Chapter 3, section 4. Research in emergency situation
ClinO – see in particular articles
- Art. 7 Informed Consent
- Art. 8 Exception to the written form
- Art. 9 Consequences of revocation of consent
- Art. 15 Post hoc consent in emergency situations
HRO – see in particular articles and chapter
- Art. 8 Informed Consent
- Art. 9 Exception to the written form
- Art. 10 Consequences of revocation of consent
- Art.11 Research projects in emergency situations
- Art. 41 Research involving deceased persons
- Art. 44 Informed consent involving embryos and foetuses
- Chapter 3, section 2. Informed consent and information in further use of biological material and health-related data